Luminex Q3 Revenues Soar on Strong xMAP Sales

Oct 25, 2007

NEW YORK (GenomeWeb News) – Luminex yesterday reported a 55 percent increase in third-quarter revenues, driven by robust sales of its flagship xMAP technology.

Total revenues for the three months ended Sept. 30 rose to $19.4 million from $12.5 million in the third quarter of 2006.

The quarter’s results included revenue from Tm Bioscience, which Luminex acquired in March and renamed Luminex Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Try the Other Version

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

You Do Your Way

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

CRISPR Discussions

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

This Week in Science

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Main menu